Vol. 1, Issue 10, Part K (2015)

Abstract
Herceptin contains the active substance trastuzumab (anti-p185, rhuMab HER2), which is a humanised monoclonal antibody that binds to the HER2 protein. Trastuzumab received marketing approval from the US Food and Drug Administration Sep. 25, 1998 for the treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein. This review describes the overview of trastuzumab including mechanism of action, indications and adverse reactions.